Fleury began nearly a century ago as a single clinical-analysis laboratory in São Paulo and is now the largest listed pure-play medical diagnostics company in Brazil. It runs a network of brands that together handle everything from routine blood tests to complex genetic exams and infusions, serving roughly 150 million tests each year. Full nameFleury S.A. Tickers / exchangeFLRY3 / B3 (São Paulo) HeadquartersSão Paulo, SP, Brazil SectorHealthcare – Diagnostics & Research Employees~29,000 Market valueR$9.02 billion (US$1.76 billion) Yearly salesR$8.49 billion (US$1.66 billion) Net profitR$612.8 million (US$119.9 million) Net margin7.2% …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
Brazil Q2 Earnings: Fleury Profit Jumps 46%; Energisa Swings to Loss
Fleury Closes $41m Femme Buy to Build Brazil’s Women’s-Health Network
Fleury Q1 Profit +12% Beats Consensus in Centennial Year
Brazil’s Fleury Grows Profit 15% as Diagnostics Revenue Climbs
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →